Research analyst – Metro Research http://metroresearch.org/ Tue, 20 Sep 2022 09:38:19 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://metroresearch.org/wp-content/uploads/2021/06/cropped-icon-32x32.png Research analyst – Metro Research http://metroresearch.org/ 32 32 Cyxtera Technologies, Inc. (NASDAQ:CYXT) Short Interest Down 8.1% in August https://metroresearch.org/cyxtera-technologies-inc-nasdaqcyxt-short-interest-down-8-1-in-august/ Tue, 20 Sep 2022 09:19:10 +0000 https://metroresearch.org/cyxtera-technologies-inc-nasdaqcyxt-short-interest-down-8-1-in-august/ Cyxtera Technologies, Inc. (NASDAQ: CYXT – Get a rating) benefited from a sharp drop in short-term interest rates during August. As of August 31, there was short interest totaling 5,690,000 shares, down 8.1% from the total of 6,190,000 shares as of August 15. Currently, 7.8% of the company’s shares are sold short. Based on an […]]]>

Cyxtera Technologies, Inc. (NASDAQ: CYXT – Get a rating) benefited from a sharp drop in short-term interest rates during August. As of August 31, there was short interest totaling 5,690,000 shares, down 8.1% from the total of 6,190,000 shares as of August 15. Currently, 7.8% of the company’s shares are sold short. Based on an average trading volume of 648,700 shares, the day-to-cover ratio is currently 8.8 days.

Insider Buying and Selling at Cyxtera Technologies

In other news from Cyxtera Technologies, COO James Randolph Rowland sold 9,885 shares in a trade on Monday August 8th. The shares were sold at an average price of $12.29, for a total transaction of $121,486.65. Following the transaction, the COO now directly owns 91,052 shares of the company, valued at approximately $1,119,029.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, available at this hyperlink. In other Cyxtera Technologies news, CFO Carlos Ignacio Sagasta sold 11,229 shares in a trade on Monday August 8th. The shares were sold at an average price of $12.29, for a total transaction of $138,004.41. Following the transaction, the CFO now directly owns 89,708 shares of the company, valued at approximately $1,102,511.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, available at this hyperlink. Additionally, COO James Randolph Rowland sold 9,885 shares of the company in a trade dated Monday, August 8. The stock was sold at an average price of $12.29, for a total transaction of $121,486.65. Following completion of the transaction, the COO now owns 91,052 shares of the company, valued at $1,119,029.08. Disclosure of this sale can be found here. Insiders sold 147,318 shares of the company worth $1,762,105 in the past ninety days. 73.20% of the shares are held by insiders.

Hedge funds weigh on Cyxtera Technologies

Several large investors have recently bought and sold shares of CYXT. Starboard Value LP increased its stake in Cyxtera Technologies by 25.7% during the 1st quarter. Starboard Value LP now owns 20,767,571 shares of the company valued at $253,780,000 after purchasing an additional 4,241,256 shares during the period. BC Partners Advisors LP increased its stake in Cyxtera Technologies by 3.5% during the 1st quarter. BC Partners Advisors LP now owns 47,676,705 shares of the company valued at $582,609,000 after purchasing an additional 1,627,561 shares during the period. State Street Corp increased its stake in Cyxtera Technologies by 102.8% in the second quarter. State Street Corp now owns 1,168,882 shares of the company valued at $13,255,000 after purchasing an additional 592,643 shares during the period. FMR LLC increased its stake in Cyxtera Technologies by 2.0% during the 2nd quarter. FMR LLC now owns 23,816,520 shares of the company valued at $270,080,000 after purchasing an additional 473,991 shares during the period. Finally, Granite Investment Partners LLC acquired a new position in Cyxtera Technologies during Q2 valued at approximately $4,508,000.

Cyxtera Technologies is trading down 3.8%

CYXT stock opened at $4.85 on Tuesday. The company has a quick ratio of 0.41, a current ratio of 0.41 and a debt ratio of 3.06. Cyxtera Technologies has a fifty-two week low of $4.69 and a fifty-two week high of $15.42. The company’s 50-day simple moving average is $9.17 and its 200-day simple moving average is $11.40.

Cyxtera Technologies (NASDAQ: CYXT – Get a rating) last released its quarterly earnings data on Thursday, August 11. The company reported ($0.27) earnings per share for the quarter, missing analyst consensus estimates of ($0.19) by ($0.08). Cyxtera Technologies posted a negative return on equity of 27.18% and a negative net margin of 27.88%. The company posted revenue of $184.10 million in the quarter, versus analyst estimates of $185.00 million. During the same period last year, the company achieved EPS of ($0.88). The company’s revenue increased 5.0% year-over-year. Analysts predict that Cyxtera Technologies will post an EPS of -0.9 for the current year.

Wall Street analysts predict growth

A number of research companies have recently published reports on CYXT. Citigroup upgraded shares of Cyxtera Technologies from a “neutral” rating to a “buy” rating and set a price target of $13.00 on the stock in a Wednesday, August 24 research report. Truist Financial raised its price target on shares of Cyxtera Technologies from $15.00 to $20.00 and gave the stock a “buy” rating in a Wednesday, June 8 research report. Royal Bank of Canada raised its price target on shares of Cyxtera Technologies from $14.00 to $16.00 in a Monday, June 6 research report. Finally, Credit Suisse Group cut its price target on shares of Cyxtera Technologies to $13.00 in a Monday, August 15 research report. One research analyst gave the stock a hold rating and seven gave the company’s stock a buy rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.83.

Cyxtera Technologies Company Profile

(Get a rating)

Cyxtera Technologies, Inc provides various data center products and services for enterprises, service providers and government agencies. It offers colocation, interconnect, deployment and retail support services; and Bare Metal, an on-demand IT infrastructure solution. The company is headquartered in Coral Gables, Florida.

Featured articles

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider Cyxtera Technologies, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Cyxtera Technologies was not on the list.

Although Cyxtera Technologies currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
Short-term stake in ImmunoGen, Inc. (NASDAQ:IMGN) decreases 13.9% https://metroresearch.org/short-term-stake-in-immunogen-inc-nasdaqimgn-decreases-13-9/ Sun, 18 Sep 2022 17:33:25 +0000 https://metroresearch.org/short-term-stake-in-immunogen-inc-nasdaqimgn-decreases-13-9/ ImmunoGen, Inc. (NASDAQ: IMGN – Get a rating) was the target of a significant drop in short interest in August. As of August 31, there was short interest totaling 12,310,000 shares, down 13.9% from the total of 14,300,000 shares as of August 15. Based on an average daily volume of 3,140,000 shares, the day-to-cover ratio […]]]>

ImmunoGen, Inc. (NASDAQ: IMGN – Get a rating) was the target of a significant drop in short interest in August. As of August 31, there was short interest totaling 12,310,000 shares, down 13.9% from the total of 14,300,000 shares as of August 15. Based on an average daily volume of 3,140,000 shares, the day-to-cover ratio is currently 3.9 days.

Hedge funds weigh on ImmunoGen

Several large investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA increased its stake in ImmunoGen by 4.1% during the 4th quarter. BNP Paribas Arbitrage SA now owns 61,561 shares of the biotech company valued at $457,000 after purchasing an additional 2,406 shares during the period. TFC Financial Management increased its stake in ImmunoGen by 18.1% in the first quarter. TFC Financial Management now owns 17,950 shares of the biotech company valued at $85,000 after buying an additional 2,750 shares during the period. Blair William & Co. IL increased its stake in ImmunoGen by 0.5% in the 1st quarter. Blair William & Co. IL now owns 538,410 shares of the biotech company valued at $2,563,000 after purchasing an additional 2,925 shares during the period. Kestra Advisory Services LLC increased its stake in ImmunoGen by 14.6% during the 1st quarter. Kestra Advisory Services LLC now owns 23,468 shares of the biotech company valued at $112,000 after purchasing an additional 2,985 shares during the period. Finally, Mackenzie Financial Corp increased its stake in ImmunoGen by 4.4% during the first quarter. Mackenzie Financial Corp now owns 80,816 shares of the biotech company valued at $385,000 after buying 3,370 additional shares during the period. Institutional investors and hedge funds own 95.58% of the company’s shares.

ImmunoGen Price Performance

IMGN shares traded down $0.34 during Friday trading hours, hitting $5.04. The stock recorded a trading volume of 8,902,983 shares, compared to an average volume of 2,536,643 shares. ImmunoGen has a 12-month minimum of $3.10 and a 12-month maximum of $7.77. The company has a 50-day simple moving average of $5.40 and a 200-day simple moving average of $4.83. The company has a market capitalization of $1.11 billion, a PE ratio of -7.30 and a beta of 0.90.

ImmunoGen (NASDAQ:IMGN – Get a rating) last released its quarterly earnings data on Friday, July 29. The biotech company reported ($0.24) earnings per share for the quarter, missing analyst consensus estimates of ($0.21) by ($0.03). ImmunoGen posted a negative return on equity of 67.02% and a negative net margin of 179.64%. The company posted revenue of $14.20 million in the quarter, compared to analyst estimates of $16.18 million. During the same period last year, the company achieved EPS of ($0.15). The company’s revenue was down 16.0% year over year. On average, stock analysts expect ImmunoGen to post -0.89 earnings per share for the current year.

A Wall Street analyst gives his opinion

A number of research analysts have commented on IMGN shares. StockNews.com downgraded ImmunoGen’s shares from a “hold” to a “sell” rating in a Monday, Aug. 1 research note. Barclays began covering ImmunoGen shares in a report on Friday, September 9. They set an “overweight” rating and a target price of $8.00 on the stock. One equity research analyst has assigned the stock a sell rating, two have issued a hold rating and three have assigned the stock a buy rating. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $9.80.

About ImmunoGen

(Get a rating)

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies (ADCs) to treat cancer. The Company’s product candidates include mirvetuximab soravtansine, an ADC targeting the folate receptor alpha (FRa), which is in a Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, an ADC targeting CD123 that is in a Phase II clinical trial for the treatment of acute myeloid leukemia and blast plasmacytoid dendritic cell neoplasm.

Recommended Stories

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider ImmunoGen, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and ImmunoGen wasn’t on the list.

Although ImmunoGen currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
Insider Sale: PayPal Holdings, Inc. (NASDAQ: PYPL) Insider Sells 150 Shares https://metroresearch.org/insider-sale-paypal-holdings-inc-nasdaq-pypl-insider-sells-150-shares/ Sat, 17 Sep 2022 00:31:59 +0000 https://metroresearch.org/insider-sale-paypal-holdings-inc-nasdaq-pypl-insider-sells-150-shares/ PayPal Holdings, Inc. (NASDAQ: PYPL – Get a rating) insider Gabrielle Scheibe sold 150 shares of the company in a trade dated Friday, September 16. The shares were sold at an average price of $94.95, for a total value of $14,242.50. Following the completion of the sale, the insider now directly owns 8,927 shares of […]]]>

PayPal Holdings, Inc. (NASDAQ: PYPL – Get a rating) insider Gabrielle Scheibe sold 150 shares of the company in a trade dated Friday, September 16. The shares were sold at an average price of $94.95, for a total value of $14,242.50. Following the completion of the sale, the insider now directly owns 8,927 shares of the company, valued at $847,618.65. The sale was disclosed in a filing with the SEC, which is available via this hyperlink.

PayPal Price Performance

Shares of NASDAQ PYPL traded at $2.40 during Friday’s midday session, hitting $94.00. The company had a trading volume of 17,180,983 shares, compared to its average volume of 17,977,574. The company has a leverage ratio of 0.52, a quick ratio of 1.23 and a current ratio of 1.23. PayPal Holdings, Inc. has a one-year low of $67.58 and a one-year high of $282.50. The company has a market capitalization of $108.71 billion, a price-earnings ratio of 54.02, a PEG ratio of 2.09 and a beta of 1.45. The company’s 50-day simple moving average is $89.80 and its 200-day simple moving average is $90.94.

PayPal (NASDAQ: PYPL – Get a rating) last released its quarterly earnings data on Tuesday, August 2. The credit service provider reported earnings per share of $0.65 for the quarter, beating the consensus estimate of $0.54 by $0.11. The company posted revenue of $6.81 billion for the quarter, versus analyst estimates of $6.76 billion. PayPal had a return on equity of 16.79% and a net margin of 7.79%. On average, research analysts predict that PayPal Holdings, Inc. will post earnings per share of 2.89 for the current fiscal year.

A Wall Street analyst gives his opinion

Several stock analysts have recently released reports on PYPL shares. Sumitomo Mitsui Financial Group has downgraded PayPal from an ‘underperforming’ rating to a ‘neutral’ rating and raised its price target for the company from $90.00 to $100.00 in a research report from the Wednesday, August 3. Piper Sandler cut its price target on PayPal from $140.00 to $93.00 and set an “overweight” rating for the company in a Wednesday, July 6 research report. Truist Financial raised its price target on PayPal from $80.00 to $108.00 and gave the company a “hold” rating in a Wednesday, Aug. 3 research report. Credit Suisse Group raised its price target on PayPal from $95.00 to $110.00 and gave the stock an “outperform” rating in a Wednesday, Aug. 3 research report. Finally, UBS Group reduced its price target on PayPal from $143.00 to $136.00 and set a “buy” rating for the company in a Wednesday, August 3 research report. One research analyst rated the stock with a sell rating, twelve gave the stock a hold rating, and thirty-two gave the stock a buy rating. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.93.

PayPal Institutional Commerce

Several large investors have recently bought and sold shares of PYPL. Intelligent Financial Strategies acquired a new stake in PayPal stock during the fourth quarter worth approximately $37,000. Oliver Lagore Vanvalin Investment Group bought a new stake in PayPal in the first quarter worth around $28,000. Addison Advisors LLC increased its stake in PayPal by 100.7% in the first quarter. Addison Advisors LLC now owns 279 shares of the credit service provider worth $32,000 after buying an additional 140 shares in the last quarter. Vectors Research Management LLC increased its stake in PayPal by 116.5% in the fourth quarter. Vectors Research Management LLC now owns 301 shares of the credit service provider worth $57,000 after buying 162 additional shares in the last quarter. Finally, Disciplined Investments LLC increased its stake in PayPal to 82.9% in the first quarter. Disciplined Investments LLC now owns 311 shares of the credit service provider worth $36,000 after buying 141 additional shares in the last quarter. 70.67% of the shares are held by institutional investors and hedge funds.

PayPal Company Profile

(Get a rating)

PayPal Holdings, Inc operates a technology platform that enables digital payments on behalf of merchants and consumers worldwide. It provides payment solutions under the names PayPal, PayPal Credit, Braintree, Venmo, Xoom, Zettle, Hyperwallet, Honey and Paidy. The company’s payment platform enables consumers to send and receive payments in approximately 200 markets and in approximately 100 currencies, withdraw funds to their bank accounts in 56 currencies, and store balances in their PayPal accounts in 25 currencies.

Further reading

Insider buying and selling by quarter for PayPal (NASDAQ:PYPL)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider PayPal, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes viral…and PayPal wasn’t on the list.

Although PayPal currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
Scor Se (OTCMKTS:SCRYY) Short Interest Up 84.0% in August https://metroresearch.org/scor-se-otcmktsscryy-short-interest-up-84-0-in-august/ Thu, 15 Sep 2022 01:09:57 +0000 https://metroresearch.org/scor-se-otcmktsscryy-short-interest-up-84-0-in-august/ Scor Se (OTCMKTS:SCRYY – Get a rating) saw strong growth in short-term interest in August. As of August 31, there were short interests totaling 41,400 shares, a growth of 84.0% from the total of 22,500 shares as of August 15. Based on an average daily volume of 104,800 shares, the day-to-cover ratio is currently 0.4 […]]]>

Scor Se (OTCMKTS:SCRYY – Get a rating) saw strong growth in short-term interest in August. As of August 31, there were short interests totaling 41,400 shares, a growth of 84.0% from the total of 22,500 shares as of August 15. Based on an average daily volume of 104,800 shares, the day-to-cover ratio is currently 0.4 days.

Scor price performance

Shares of Scor traded down $0.10 during Wednesday’s session, hitting $1.74. 1,211 shares of the company were traded, against an average volume of 22,038. The company has a quick ratio of 6.71, a current ratio of 2.95 and a leverage ratio of 0.47. Scor has a fifty-two week low of $1.55 and a fifty-two week high of $3.73. The stock has a market capitalization of $3.25 billion, a price-earnings ratio of -15.82 and a beta of 1.27. The company has a 50-day moving average price of $1.80 and a 200-day moving average price of $2.41.

Scor (OTCMKTS:SCRYY – Get a rating) last released its quarterly earnings data on Thursday, July 28. The financial services provider reported ($0.10) earnings per share (EPS) for the quarter. Scor posted a negative return on equity of 2.55% and a negative net margin of 0.96%. The company posted revenue of $4.13 billion for the quarter. On average, equity analysts expect Scor to post 0.02 earnings per share for the current financial year.

Changes to analyst ratings

A d Allied robotics

Last month to invest in a startup that launches the golden age of robotics – Ends 09/29

88% of businesses want robots, but most don’t have the money or the expertise to use them. Ally Robotics has designed one that costs 70% less and requires no code to operate. Invest in Ally Robotics before their raise ends on September 29.

A number of brokerages have weighed in on SCRYY. JPMorgan Chase & Co. lowered its price target on Scor from €24.50 ($25.00) to €16.00 ($16.33) and set an “underweight” rating on the stock in a report from Friday, July 29. HSBC downgraded Scor from a “buy” rating to a “hold” rating in a Tuesday, June 14 research note. Morgan Stanley lowered its price target on Scor from €32.00 ($32.65) to €30.00 ($30.61) in a Thursday, September 8 research note. Keefe, Bruyette & Woods raised Scor from an “underperforming” rating to an “overperforming” rating in a Thursday, August 25 research rating. Finally, Berenberg Bank reduced its price target on Scor from €35.00 ($35.71) to €28.00 ($28.57) and set a “buy” rating on the stock in a research from Friday, July 29. One research analyst rated the stock with a sell rating, three assigned a hold rating and six assigned the company a buy rating. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $25.93.

About Scor

(Get a rating)

SCOR SE, together with its subsidiaries, offers life and non-life reinsurance products in Europe, the Middle East, Africa, America, Latin America and Asia-Pacific. It operates through two segments, SCOR Global P&C and SCOR Global Life. The SCOR Global P&C segment offers reinsurance products in the areas of property and casualty, motor, tort treaties, credit and surety, decennial insurance, aviation, marine and marine. energy, engineering, agricultural risks and property disasters; specialty insurance products, including business solutions, political and credit risk, cyber liability and environmental liability; and business ventures and partnerships.

See also

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider Scor, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Scor wasn’t on the list.

While Scor currently enjoys a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
Guidehouse Insights estimates the monitoring and controls market for solar and storage technologies will reach $3 billion by 2031 https://metroresearch.org/guidehouse-insights-estimates-the-monitoring-and-controls-market-for-solar-and-storage-technologies-will-reach-3-billion-by-2031/ Tue, 13 Sep 2022 09:15:00 +0000 https://metroresearch.org/guidehouse-insights-estimates-the-monitoring-and-controls-market-for-solar-and-storage-technologies-will-reach-3-billion-by-2031/ Market drivers include booming adoption rates for solar power and storage, as well as demands for efficiency and security BOULDER, Col., September 13, 2022 /PRNewswire/ — A new report from Glimpses of the House of Guides explores the monitoring and controls (M&C) market for solar and storage technologies. (PRNewsfoto/Guidehouse Insights) As the market for renewable […]]]>

Market drivers include booming adoption rates for solar power and storage, as well as demands for efficiency and security

BOULDER, Col., September 13, 2022 /PRNewswire/ — A new report from Glimpses of the House of Guides explores the monitoring and controls (M&C) market for solar and storage technologies.

(PRNewsfoto/Guidehouse Insights)

As the market for renewable energy systems, such as solar PV and energy storage, continues to proliferate around the world, industry stakeholders are increasingly recognizing the enhanced value proposition that M&C solutions can offer. These solutions can have a significant effect on optimizing overall energy cost using sophisticated data analytics and sensors to detect any operational issues on these assets. According to a new report from Guidehouse Insights, annual revenue additions for the solar power and M&C storage market are expected to reach nearly $3 billion by 2031.

“From SCADA gateways and data loggers to performance monitoring and predictive maintenance tools, the combination of sensing and measurement technologies and data analytics provides asset owners with more actionable insights to improve the operational efficiency and lower lifetime costs,” says Michael Kelly, senior research analyst at Guidehouse Insights. “M&C solutions that can quickly identify and accurately detect yield gaps are uniquely positioned to succeed in this growing market.

Multiple dynamics are responsible for the growth of the M&C market and the barriers it faces. The main drivers of growth are the booming adoption rates of solar power and storage, as well as efficiency, security requirements and the need for predictive maintenance for remote assets. Still, challenges such as cost, lack of data sharing, and the need for continuous technology updates could hamper M&C’s growth, according to the report.

The report, Solar and storage monitoring and controls, outlines the key trends and industry players that are currently active in the M&C space. As M&C may be a rapidly evolving set of technologies, further advancements are likely, particularly in the form of AI and machine learning, in the years to come. This report determines that despite the decline in the cost of M&C capacities, revenues from this market across solar and storage will continue to increase largely due to the acceleration of solar and storage system deployments. Guidehouse Insights expects annual revenue additions for the solar power and storage market to reach nearly $3 billion by 2031. An executive summary of the report is available for free download from the Guidehouse Insights website.

About Guidehouse Insights

Guidehouse Insights, the dedicated market intelligence arm of Guidehouse, provides research, data and benchmarking services for today’s rapidly changing and highly regulated industries. Our knowledge is based on an in-depth analysis of global clean technology markets. The team’s research methodology combines supply-side industry analysis, primary end-user research, and demand assessment, coupled with an in-depth review of technology trends, to provide a comprehensive view emerging resilient infrastructure systems. Additional information on Guidehouse Insights is available at www.guidehouseinsights.com.

About Guidehouse

Guidehouse is a leading global provider of advisory services to the public sector and commercial markets, with extensive risk management, technology and advisory capabilities. By combining our public and private sector expertise, we help our clients address their most complex challenges and overcome significant regulatory pressures focused on transformational change, business resilience and technology-driven innovation. Through a range of consulting, advisory, outsourcing and digital services, we create scalable and innovative solutions that help our clients navigate complexity and position them for future growth and success. The company has more than 13,000 professionals in more than 50 locations worldwide. Guidehouse is a Veritas Capital portfolio company, led by seasoned professionals with proven and diverse expertise in traditional and emerging technologies, markets and agenda issues that drive national and global economies. For more information, please visit www.guidehouse.com.

* The information contained in this press release regarding the report, Solar and storage monitoring and controls, is a summary and reflects current expectations of Guidehouse Insights based on market data and trend analysis. Forecasts and market expectations are inherently uncertain and actual results may differ materially from those contained in this press release or report. Please refer to the full report for a complete understanding of the assumptions underlying the report’s findings and the methodologies used to create the report. Neither Guidehouse Insights nor Guidehouse undertakes to update the information contained in this press release or the report.

For more information contact:
Cecile Fradkin
+1.646.941.9139
cfradkin@scprgroup.com

Quote

Quote

Show original content to download multimedia:https://www.prnewswire.com/news-releases/guidehouse-insights-estimates-monitoring-and-controls-market-for-solar-and-storage-technologies-will-reach-3-billion-by-2031- 301621871.html

SOURCE Guidehouse Insights

]]>
How to invest in water as droughts and shortages dominate the news https://metroresearch.org/how-to-invest-in-water-as-droughts-and-shortages-dominate-the-news/ Sat, 10 Sep 2022 19:00:00 +0000 https://metroresearch.org/how-to-invest-in-water-as-droughts-and-shortages-dominate-the-news/ By Myra P. Saefong Not all water investments are winners: analyst Water has become a popular topic these days, given the widespread drought conditions around the world and the water crisis in Jackson, Mississippi. This does not automatically translate to a win-win when it comes to investing in the sector. “As water megatrends continue to […]]]>

By Myra P. Saefong

Not all water investments are winners: analyst

Water has become a popular topic these days, given the widespread drought conditions around the world and the water crisis in Jackson, Mississippi. This does not automatically translate to a win-win when it comes to investing in the sector.

“As water megatrends continue to dominate the headlines, the investment implications are more complicated,” says Deane Dray, managing director and cross-industry analyst at RBC Capital Markets.

“One of the biggest myths is that all water investments must win,” given all the supply and demand imbalances, droughts and drinking water fiascos like Jackson’s, he said. “Too many people think that just being in a water-related business automatically makes it a good investment. That’s just not the case.”

Most water exchange-traded funds were trading lower this year as of September 6, with First Trust Water (FIW) down 18%, Invesco Global Water (PIO) down 28% and Invesco Water Resources (PHO) down 19%. Shares of water technology provider Xylem Inc. (XYL) were down 23% and utility company American Water Works Co. (AWK) was down 21%.

On the Chicago Mercantile Exchange (CME), however, water futures based on the Nasdaq Veles California Water Index were trading at $1,165 per acre-foot, up about 21% from the l ‘last year.

Investors have different options for investing in the water industry, “from desalination technology to companies supplying water at the municipal level and those transporting water,” says Andrew Chanin, CEO of ProcureAM and issuer of the Procure Disaster Recovery Strategy (FEMA). There is no simple solution, so “diversification may be an approach investors consider to address the growing water crisis,” he says.

Among investment choices, the future of water can help determine whether there are concerns about scarcity, Chanin adds. Investing in water ETFs, meanwhile, shows an understanding that there is a “looming crisis and that we are even more dependent on these companies to develop solutions.” And companies providing water technology, infrastructure and transport, as well as methods of creating clean water, such as desalination, could be “very important during cycles of drought and water scarcity. “.

In stark sign of the extent of water shortages, the United States Bureau of Reclamation reported that the water level of Lake Mead, on the Arizona-Nevada border, the nation’s largest reservoir, was only 28% full as of September 6.

“We expect the consequences of water shortages to become increasingly apparent…resulting in a corresponding increase in demand for companies that support more thoughtful approaches to water use,” says Alec Lucas, Research Analyst at Global X ETFs.

Lucas oversees his company’s suite of water and cleantech funds, such as Global X Clean Water (AQWA), which includes “pure players” – companies that generate at least 50% of their revenue from water. business operations related to the clean water industry. , he says. These companies include Xylem and American Water Works, as well as water metering and distribution products manufacturer Mueller Water Products Inc. (MWA) and water treatment and purification technology developer Ecolab Inc. ( ECL).

Dray of RBC Capital Market says there are few publicly traded “pure play” water companies, and while there are more than 50,000 water utilities in the United States, fewer than 10 are listed on the stock exchange. This limits investors’ choices in the water sector.

Still, Dray thinks Xylem, Evoque Water Technologies Corp. (AQUA) and Danaher Corp. (DHR) are “much better positioned to be winners” in high-tech water sub-sectors such as smart water systems, automation, water testing and desalination. .

-Myra P. Saefong

 

(END) Dow Jones Newswire

09-10-22 1500ET

Copyright (c) 2022 Dow Jones & Company, Inc.

]]>
JPMorgan Chase & Co. reaffirms “overweight” rating for DCC (LON:DCC) https://metroresearch.org/jpmorgan-chase-co-reaffirms-overweight-rating-for-dcc-londcc/ Fri, 09 Sep 2022 08:18:17 +0000 https://metroresearch.org/jpmorgan-chase-co-reaffirms-overweight-rating-for-dcc-londcc/ DCC (LON:DCC – Get a rating)The stock of was re-rated to “overweight” by equity research analysts at JPMorgan Chase & Co. in a research note published on Friday, LSE.Co.UK reports. They currently have a price target of 7,500 GBX ($90.62) on the stock. JPMorgan Chase & Co.the price target would point to a potential upside […]]]>

DCC (LON:DCC – Get a rating)The stock of was re-rated to “overweight” by equity research analysts at JPMorgan Chase & Co. in a research note published on Friday, LSE.Co.UK reports. They currently have a price target of 7,500 GBX ($90.62) on the stock. JPMorgan Chase & Co.the price target would point to a potential upside of 54.80% from the stock’s previous close.

CDC has been the subject of several other reports. Berenberg Bank reissued a “buy” rating and issued a price target of 7,250 GBX ($87.60) on DCC shares in a research report on Tuesday, May 17. Royal Bank of Canada downgraded DCC to an “industry performance” rating and reduced its price target for the company from 7,500 GBX ($90.62) to 5,800 GBX ($70.08) in a research note from Monday, May 30. Finally, Barclays restated an “underweight” rating and published a target price of 5,550 GBX ($67.06) on DCC shares in a research note on Tuesday, July 19. One research analyst has rated the stock with a sell rating, another has assigned a hold rating, and three have assigned the stock a buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of 6,852 GBX ($82.79).

DCC stock up 1.1%

A d x1esports

Get your in-game wallet today!

This games and media holding company brings a unique consolidation strategy and a diverse mix of experiences brought by its management team to a changing and highly fragmented space.

Shares of LON:DCC opened at 4,845 GBX ($58.54) on Friday. The company has a market capitalization of £4.78 billion and a P/E ratio of 1,533.23. The company has a quick ratio of 0.95, a current ratio of 1.37 and a debt ratio of 80.01. DCC has a 12-month minimum of 4,725 GBX ($57.09) and a 12-month maximum of 6,520 GBX ($78.78). The company has a fifty-day simple moving average of 5,158.94 GBX and a 200-day simple moving average of 5,530.91 GBX.

About DCC

(Get a rating)

DCC plc provides worldwide sales, marketing and support services. The Company’s DCC LPG segment sells and markets liquefied petroleum gas (LPG), refrigerants and natural gas. Its DCC Retail & Oil segment markets, sells and retails transportation and commercial fuels, heating oils and related products and services; operates retail gas stations; resells fuel cards; distributes oil; and provides inbound logistics, storage and refill, and outbound logistics services.

Featured Articles

Analyst recommendations for DCC (LON:DCC)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider DCC, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and DCC wasn’t on the list.

Although DCC currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
Pyramid Biosciences Appoints Biren Amin as Chief Financial and Strategy Officer https://metroresearch.org/pyramid-biosciences-appoints-biren-amin-as-chief-financial-and-strategy-officer/ Wed, 07 Sep 2022 17:19:10 +0000 https://metroresearch.org/pyramid-biosciences-appoints-biren-amin-as-chief-financial-and-strategy-officer/ Biren Amin, MS, MBA ALTHAM, Mass.–(BUSINESS WIRE)–Pyramid Biosciences, Inc.., a Boston-based clinical-stage biotechnology company focused on developing new, highly differentiated, precision cancer therapies, today announced the expansion of its management team. Biren Amin, MS, MBA joined the company as Chief Financial and Strategic Officer. Mr. Amin joins Pyramid Biosciences from Immuneering Corporation (NASDAQ: IMRX), where […]]]>

ALTHAM, Mass.–(BUSINESS WIRE)–Pyramid Biosciences, Inc.., a Boston-based clinical-stage biotechnology company focused on developing new, highly differentiated, precision cancer therapies, today announced the expansion of its management team. Biren Amin, MS, MBA joined the company as Chief Financial and Strategic Officer. Mr. Amin joins Pyramid Biosciences from Immuneering Corporation (NASDAQ: IMRX), where he previously served as the company’s Chief Financial Officer (CFO).

“We are delighted to have Biren join our leadership team, particularly during this time of significant growth for the company,” said Brian Lestini, MD, Ph.D., CEO of Pyramid Biosciences. “His accomplishments over two decades in oncology and biotechnology, both in the capital markets and in industry, are impeccable and unparalleled. As we strive to serve patients by advancing and expanding our pipeline, Biren’s strategic leadership and expertise will play a critical role in accomplishing our mission.

“I look forward to working with the exceptional team at Pyramid Biosciences as we advance our best-in-class NTRK inhibitor, PBI-200, through clinical development and diversify our pipeline,” said Mr. Amin. “My focus will be to ensure that our corporate strategy and business development activities align with our goal of bringing cutting-edge, experimental oncology therapies to society and to patients.”

Prior to joining Pyramid Biosciences, Mr. Amin served as Chief Financial Officer at Immuneering Corporation, a US-based, oncology-focused preclinical biopharmaceutical company, where he led a successful initial public offering of $120 million. Previously, Mr. Amin spent nearly two decades on Wall Street, where he built a strong track record in small and mid-cap biotechnology companies, focusing on oncology, CNS disorders, ophthalmology and rare diseases. Mr. Amin spent a decade at Jefferies Financial Group as managing director of their equity research group. Meanwhile, Mr. Amin was named Best Stock Picker in Biotechnology in 2013 by the Financial Times. Prior to joining Jefferies, Mr. Amin was an equity research analyst covering biotechnology and pharmaceuticals at several companies, including Prudential Equity Group. He started his career at Aventis Pharmaceuticals (currently part of Sanofi SA) where he held the position of Senior Manager in their Scientific Competitive Intelligence group. Mr. Amin earned his Bachelor of Science (BS) in Pharmacy from the University of Science in Philadelphia, his Master of Science (MS) in Pharmacy from Long Island University, and his Master of Business Administration (MBA) from the Stern School of Business at New York University. He currently sits on the board of the Axiom REACH Foundation.

About Pyramid Biosciences:

Founded in 2015, Pyramid Biosciences is a clinical-stage biotechnology company focused on the development of novel, highly differentiated precision therapies for cancer. Based in Boston, Massachusetts, Pyramid Biosciences is currently in clinical development of two highly selective tropomyosin receptor kinase (TRK) inhibitors. For more information, please visit: www.pyramidbio.com

]]>
ASOS (ASC) ‘Sell’ rating reaffirmed to Shore Capital https://metroresearch.org/asos-asc-sell-rating-reaffirmed-to-shore-capital/ Mon, 05 Sep 2022 20:18:55 +0000 https://metroresearch.org/asos-asc-sell-rating-reaffirmed-to-shore-capital/ ASOS (LON:ASC – Get a rating)The stock had its “sell” rating reiterated by analysts at Shore Capital in a research note released Monday to investors, MarketBeat reports. A number of other brokerages also weighed in on ASC. Goldman Sachs Group set a price target of 1,300 GBX ($15.71) on ASOS shares in a Monday, June […]]]>

ASOS (LON:ASC – Get a rating)The stock had its “sell” rating reiterated by analysts at Shore Capital in a research note released Monday to investors, MarketBeat reports.

A number of other brokerages also weighed in on ASC. Goldman Sachs Group set a price target of 1,300 GBX ($15.71) on ASOS shares in a Monday, June 20 report. JPMorgan Chase & Co. set a target price of 1,500 GBX ($18.12) on ASOS in a Wednesday, August 24 report. Barclays lowered its price target on ASOS from 1,075 GBX ($12.99) to 920 GBX ($11.12) and set an ‘equal weight’ rating for the company in a Tuesday, August 30 research note . Berenberg Bank cut its price target on ASOS from 2,500 GBX ($30.21) to 1,800 GBX ($21.75) and set a ‘buy’ rating on the stock in a research note Wednesday, August 31. Finally, Royal Bank of Canada set a target price of 2,000 GBX ($24.17) on ASOS shares in a Friday, June 17 research report. One research analyst rated the stock with a sell rating, four gave the stock a hold rating, and seven gave the stock a buy rating. According to data from MarketBeat, ASOS has an average rating of “moderate buy” and an average target price of 2,204.62 GBX ($26.64).

ASOS down 6.8%

ASC fell 46.89 GBX ($0.57) during Monday’s trading, reaching 638.11 GBX ($7.71). Shares of the company had a trading volume of 991,358 shares, compared to an average volume of 644,085. ASOS has a 12-month low of 621 GBX ($7.50) and a 12-month high of 3,583 GBX ($43.29). The stock has a market capitalization of £637.72 million and a PE ratio of 2,200.37. The company’s 50-day rolling average price is 932.07 GBX and its 200-day rolling average price is 1,325.81 GBX. The company has a debt ratio of 77.77, a current ratio of 1.59 and a quick ratio of 0.52.

Insider buying and selling

A d Stansberry Research

CEO of largest private equity firm predicts ‘social unrest’

The CEO of Blackstone (the largest US private equity firm) recently publicly announced “social unrest”.

In other ASOS news, insider Jørgen Lindemann bought 57,392 shares of the company in a trade dated Thursday, June 16. The share was acquired at an average cost of 854 GBX ($10.32) per share, with a total value of £490,127.68 ($592,227.74).

About ASOS

(Get a rating)

ASOS Plc operates as an online fashion retailer worldwide. It offers feminine and masculine products. The Company sells its products under the ASOS Design, ASOS Edition, ASOS 4505, Collusion, Reclaimed Vintage, Topshop, Topman, Miss Selfridge and HIIT brands, as well as through third-party brands. He is also involved in employing marketing staff and payment processing companies.

See also

Analyst recommendations for ASOS (LON:ASC)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider ASOS, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes viral…and ASOS wasn’t on the list.

While ASOS currently has a “moderate buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
SeaSpine Holdings Co. (NASDAQ:SPNE) Receives an Average “Moderate Buy” Recommendation from Brokerages https://metroresearch.org/seaspine-holdings-co-nasdaqspne-receives-an-average-moderate-buy-recommendation-from-brokerages/ Sun, 04 Sep 2022 06:44:22 +0000 https://metroresearch.org/seaspine-holdings-co-nasdaqspne-receives-an-average-moderate-buy-recommendation-from-brokerages/ Shares of SeaSpine Holdings Co. (NASDAQ: SPNE – Get a rating) earned an average recommendation of “moderate buy” from the eight research companies that currently cover the business, reports Marketbeat Ratings. One equity research analyst gave the stock a hold rating and five gave the company a buy rating. The 12-month average price target among […]]]>

Shares of SeaSpine Holdings Co. (NASDAQ: SPNE – Get a rating) earned an average recommendation of “moderate buy” from the eight research companies that currently cover the business, reports Marketbeat Ratings. One equity research analyst gave the stock a hold rating and five gave the company a buy rating. The 12-month average price target among analysts who have reported on the stock in the past year is $30.00.

A number of research companies have recently published reports on NBS. Piper Sandler lowered its price target on SeaSpine from $21.00 to $12.00 and set an “overweight” rating on the stock in a Wednesday, Aug. 3 research report. BTIG Research lowered its target price on SeaSpine from $23.00 to $19.00 in a research report Thursday, June 30. StockNews.com upgraded SeaSpine from a “sell” rating to a “hold” rating in a Thursday, August 4, research report. Finally, Truist Financial lowered its price target on SeaSpine from $20.00 to $12.00 and set a “buy” rating on the stock in a Wednesday, July 20 research report.

SeaSpine Share Performance

SeaSpine shares opened at $6.43 on Friday. The company has a market capitalization of $239.12 million, a price-earnings ratio of -3.51 and a beta of 1.39. The stock’s 50-day moving average is $6.36 and its 200-day moving average is $8.79. SeaSpine has a one-year low of $5.54 and a one-year high of $17.34. The company has a debt ratio of 0.09, a current ratio of 3.49 and a quick ratio of 1.91.

A d Legacy search

Sell ​​all shares except ONE

Markets are down… But Jeff Clark doesn’t care because he ignores almost every action in the market except ONE. He lives financially free by trading this stock once a month…

SeaSpine (NASDAQ: SPNE – Get a rating) last reported results on Tuesday, August 2. The medical equipment supplier reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). The company posted revenue of $56.32 million in the quarter, compared to analyst estimates of $54.34 million. SeaSpine had a negative net margin of 32.03% and a negative return on equity of 21.90%. During the same period of the previous year, the company posted an EPS of ($0.34). Stock analysts predict SeaSpine will post -1.47 earnings per share for the current fiscal year.

Insiders place their bets

In other SeaSpine news, an insider Beautiful Standish sold 50,000 shares of the company in a transaction that took place on Thursday, July 14. The stock was sold at an average price of $5.73, for a total transaction of $286,500.00. The sale was disclosed in a filing with the SEC, accessible via the SEC website. Insiders of the company own 9.32% of the shares of the company.

Hedge funds weigh on SeaSpine

Institutional investors and hedge funds have recently changed their positions in the company. BNP Paribas Arbitrage SA increased its position in SeaSpine shares by 188.0% in the second quarter. BNP Paribas Arbitrage SA now owns 7,913 shares of the medical equipment supplier valued at $45,000 after buying an additional 5,165 shares in the last quarter. Amalgamated Bank purchased a new equity stake in SeaSpine in the first quarter worth approximately $55,000. AQR Capital Management LLC purchased a new equity stake in SeaSpine in the second quarter worth approximately $60,000. SG Americas Securities LLC purchased a new equity stake in SeaSpine in the second quarter valued at approximately $71,000. Finally, Bank of Montreal Can bought a new equity stake in SeaSpine in the second quarter valued at around $75,000. Institutional investors and hedge funds hold 72.07% of the company’s shares.

SeaSpine Company Profile

(Get a rating)

SeaSpine Holdings Corporation, a medical technology company, is focused on designing, developing and marketing surgical solutions for the treatment of spinal disorders in the United States and around the world. It offers orthobiologic and spinal implant solutions to neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic and cervical spine.

Recommended Stories

Analyst Recommendations for SeaSpine (NASDAQ: SPNE)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider SeaSpine, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and SeaSpine wasn’t on the list.

Although SeaSpine currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>